Navigation Links
A New Drug for Halting Metastatic Kidney Cancer

A recent research reports the efficacy of a pharmaceutical drug named Sunitinib in halting the progress of metastatic kidney cancer. A comparative study of interferon and// sunitinib treatments found that sunitinib is more efficient in halting the progress of metastatic kidney cancer.

The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department.

To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research.

Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effects can occur and have to be taken into consideration - hypothyroidism, high blood pressure and fatigue.

Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer.

The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumors, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is t o be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Anti-Retrovirals Capable of Halting Mental Illness in HIV Patients
2. Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis
3. IMP3 the Novel Biomarker for Metastatic Cancer
4. Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer
5. Is Diabetes the Leading Cause of Kidney Failure in India
6. Kidney Stones - Interesting New Research implicates bacteria as its cause
7. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
8. New Dietary Approach To Manage Kidney Stones
9. Kidney cancer on the rise
10. Kidney function can be affected by lead exposure
11. Kidney Failure after Non-Kidney Transplants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... the GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the ... will be an opportunity for area-residents to celebrate two great years while also ...
(Date:3/27/2017)... ... March 27, 2017 , ... The homeowner improvement and repair market ... utilizing DIY and unlicensed contractors for renovations is also on the rise. Per a ... 2015, and of those, 42% failed to use a licensed contractor.(2) The risks associated ...
(Date:3/26/2017)... ... March 26, 2017 , ... Local physician ... 100 Award, a prestigious award honoring the top influencers on RealSelf—the most trusted ... connect with doctors and clinics. , In 2016, more than 82 million people ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce ... large subjects. The ELITE DXA has an active scan window, which is more than ... to fit in the scan area could not undergo an accurate total body bone density ...
(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its ... time by providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics ... trauma education developed in cooperation with the American College of Surgeons to promote ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... 2017 Arena Pharmaceuticals, Inc. (NASDAQ: ... small molecule drugs across multiple therapeutic areas, today announced that ... will present a corporate update at the 16th Annual Needham ... conference will take place April 4-5, 2017 at the Westin ... , NY.  A live audio webcast of ...
Breaking Medicine Technology: